Lung Cancer Treatments and Mutations

Özet henüz yok.

• BİLGİN DEMİR
• MUSTAFA ERSOY

Brain metastases are common in metastatic non-small cell lung cancer (NSCLC) and portend poor outcomes, yet prognostic determinants—particularly whether brain metastases are present at diagnosis or develop during follow-up—remain incompletely characterized in driver-negative patients treated with first-line platinum-b…

Aims: To retrospectively evaluate the demographic, epidemiological, and clinical characteristics of patients diagnosed with lung cancer. Methods: Patients diagnosed and treated for lung cancer in our medical oncology clinic were included in the study. Patient records were obtained retrospectively from the electronic d…

Aim: This study aims to evaluate the response of brain metastases to whole-brain radiotherapy (WBRT) and the role of this treatment in influencing that response.Material and Methods: The study involved eighteen patients who received WBRT for brain metastases either at the time of diagnosis or during the course of thei…

Background/Objectives: KRAS mutations are among the most common oncogenic driver alterations in non-small cell lung cancer (NSCLC) and define a biologically heterogeneous disease. In the current era of molecular oncology, with targeted therapies increasingly incorporated into clinical practice, the prognostic relevanc…

OBJECTIVE: Lung cancer is currently the leading cause of cancer-related death in men and the second most common cause in women worldwide. In the 9th edition of the TNM classification, N2 lymph node involvement has been divided into two subgroups: N2a and N2b. In this study, we aimed to examine the differences within t…

Özet henüz yok.

Lung cancer patients are frail because they are usually diagnosed at an advanced age, are often accompanied by comorbidities, and are at high risk of chemotherapy toxicity. Choosing a safe and correct treatment is very important. In this study, we investigated the ability of VES-13, which measures patient frailty, to…

Özet henüz yok.

Özet henüz yok.

Özet henüz yok.

BACKGROUND: c-MYC and enhancer of zeste homolog 2 (EZH2) are key regulators of cell proliferation and epigenetic reprogramming and have been implicated in the pathogenesis and progression of lung carcinoma. However, their clinicopathological and prognostic relevance in routine practice remains incompletely defined. Th…